Corporate Team Represents Ultragenyx in its IPO
Ropes & Gray represented Ultragenyx Pharmaceuticals, a development-stage biotechnology company focused on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases, in its $120 million initial public offering.
The Ropes & Gray team included benefits counsel Allie Alperovich.